Trending Down-0.0200 (-1.5038%)
  • Bid / Lots
    1.2500/ 50
  • Ask / Lots
    1.3200/ 15
  • Open / Previous Close
    1.3400 / 1.3300
  • Day Range
    Low 1.2399
    High 1.3600
  • 52 Week Range
    Low 1.1600
    High 3.1700
  • Volume
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 1.33
09:32 ET22041.33
09:34 ET4651.3123
09:36 ET3111.32
09:43 ET15891.3101
09:45 ET3331.315
09:48 ET10001.3199
10:24 ET37191.34
11:00 ET5001.33
11:06 ET1001.3383
11:11 ET1001.3387
11:13 ET15311.34
11:18 ET19001.3499
11:40 ET1001.345
11:47 ET9001.349
11:49 ET36391.3466
12:25 ET5001.355
12:32 ET33381.358
12:57 ET29331.3201
01:12 ET1761.3255
01:14 ET11001.35
01:28 ET7581.33
01:37 ET53671.31
01:39 ET1001.32
01:42 ET47001.28
01:44 ET83881.25
01:46 ET212001.24
02:08 ET10001.2801
02:11 ET1931.3
02:15 ET20751.31
02:31 ET10851.295
03:02 ET27001.29
03:07 ET50001.3099
03:16 ET9211.31
03:25 ET29591.33
03:30 ET1001.3254
03:36 ET1001.3
03:38 ET15001.29
03:39 ET30981.29
03:41 ET55151.31
03:45 ET32001.33
03:50 ET46601.325
03:54 ET81961.33
03:56 ET89231.3596
03:59 ET21661.31
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNXTC
NextCure Inc
United StatesPASG
Passage Bio Inc
United StatesNCNA
NuCana PLC
United StatesINAB
IN8BIO, Inc.
United StatesACHL
Achilles Therapeutics PLC
United StatesCGTX
Cognition Therapeutics Inc
As of 2023-09-27

Company Information

NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO) platform, it is studying various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its product candidates include NC410, NC762 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1. NC762 is a monoclonal antibody that binds specifically to human B7 homolog 4 protein (B7-H4) a protein expressed on multiple tumor types. NC525 (LAIR-1 mAb) is a LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells (LSCs).

Contact Information

9000 Virginia Manor Rd Ste 200BELTSVILLE, MD, United States 20705-4214


Independent Chairman of the Board
David Kabakoff
President, Chief Executive Officer, Director
Michael Richman
Chief Financial Officer
Steven Cobourn
Chief Operating Officer
Timothy Mayer
Senior Vice President - Development and Manufacturing
Sourav Kundu

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.